Fibrinogen and platelets in patients with acute myeloid leukaemia and thrombocytopenia

Aarhus University Hospital0 个研究点目标入组 20 人开始时间: 2019年11月19日最近更新: 2020年2月1日

适应症

试验速览

暂无简介。

•1.Patients treated for non-promyelocyte AML with intensive chemotherapy at the Department of Haematology, Aarhus University Hospital.
•2.Able to give written informed consent
•3.Above 18 years old
•4.Fertile women must have a negative pregnancy test and agree to use safe anti-conception(hormonal anti-conception or intrauterine device) for 30 days after receiving the study treatment.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1.Known inherited bleeding disorder
•2.Known serious thrombophilia(antithrombin deficiency, protein C or S deficiency, homozygous factor V Leiden)
•3.Thromboembolic disease within the past 3 months
•4.Known allergy to Riastap

发起方

Aarhus University Hospital